BR9910251A - Estimulação hematopoiética - Google Patents

Estimulação hematopoiética

Info

Publication number
BR9910251A
BR9910251A BR9910251-0A BR9910251A BR9910251A BR 9910251 A BR9910251 A BR 9910251A BR 9910251 A BR9910251 A BR 9910251A BR 9910251 A BR9910251 A BR 9910251A
Authority
BR
Brazil
Prior art keywords
hematopoietic
stimulation
hematopoietic stimulation
products
processes
Prior art date
Application number
BR9910251-0A
Other languages
English (en)
Inventor
Barbara P Wallner
Barry Jones
Glenn T Miller
Sharlene Adams
Original Assignee
Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapeutics Inc filed Critical Point Therapeutics Inc
Publication of BR9910251A publication Critical patent/BR9910251A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Treatment Devices (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

''ESTIMULAçãO HEMATOPOIéTICA'' São apresentados processos e produtos para estimulação hematopoiética, prevenção de baixos níveis de células hematopoiéticas e produção de números aumentados de células hematopoiéticas e sang³íneas maduras. Os processos e os produtos podem ser usados tanto in vivo, quanto in vitro.
BR9910251-0A 1998-05-04 1999-05-03 Estimulação hematopoiética BR9910251A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8412898P 1998-05-04 1998-05-04
PCT/US1999/009652 WO1999056753A1 (en) 1998-05-04 1999-05-03 Hematopoietic stimulation

Publications (1)

Publication Number Publication Date
BR9910251A true BR9910251A (pt) 2001-01-02

Family

ID=22183048

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910251-0A BR9910251A (pt) 1998-05-04 1999-05-03 Estimulação hematopoiética

Country Status (15)

Country Link
US (4) US6300314B1 (pt)
EP (1) EP1075266A1 (pt)
JP (1) JP2002513762A (pt)
KR (1) KR20010052302A (pt)
AR (1) AR023628A1 (pt)
AU (2) AU770319C (pt)
BR (1) BR9910251A (pt)
CA (1) CA2331122A1 (pt)
IL (1) IL139247A0 (pt)
MY (1) MY132924A (pt)
NO (1) NO20005488L (pt)
NZ (1) NZ507730A (pt)
PE (1) PE20000481A1 (pt)
TW (1) TWI252107B (pt)
WO (1) WO1999056753A1 (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304206A1 (en) * 1997-09-29 1999-04-08 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
MY132924A (en) * 1998-05-04 2007-10-31 Point Therapeutics Inc Hematopoietic stimulation
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP2206772A3 (en) 2000-12-06 2010-08-04 Robert J. Hariri Method of collecting placental stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2002055088A1 (en) 2001-01-16 2002-07-18 Nippon Kayaku Kabushiki Kaisha Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
EP2336299A1 (en) * 2001-02-14 2011-06-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
EP1487471A4 (en) * 2001-11-26 2010-03-10 Tufts College METHOD FOR TREATING AUTOIMMUNE DISEASES AND ASSOCIATED REAGENTS
EP2316470A3 (en) * 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
DE60226648D1 (de) * 2001-12-17 2008-06-26 Koninkl Philips Electronics Nv Verfahren der kernspintomographie
US7700090B2 (en) 2002-02-13 2010-04-20 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
CA2484551A1 (en) * 2002-04-30 2003-11-13 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
AU2003248921A1 (en) * 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
KR101042448B1 (ko) 2002-11-26 2011-06-16 안트로제네시스 코포레이션 세포요법제, 세포요법제 단위 및 이를 이용한 치료방법
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1689757B1 (en) * 2003-11-12 2014-08-27 Phenomix Corporation Heterocyclic boronic acid compounds
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR101292707B1 (ko) * 2004-02-23 2013-08-02 트러스티즈 오브 터프츠 칼리지 디펩티딜펩티다아제 ⅳ의 억제제
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
US20080112933A1 (en) * 2004-11-08 2008-05-15 Scadden David T Methods and Compositions for Increasing Stem Cell Homing Using Gas Activators
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2624925C (en) 2005-10-13 2014-09-30 Anthrogenesis Corporation Immunomodulation using placental stem cells
ES2708933T3 (es) 2005-12-29 2019-04-12 Celularity Inc Poblaciones de células madre placentarias
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2117543A4 (en) * 2007-02-01 2011-09-28 Nephrogen Llc POTENTIALIZATION OF THE IMPLANTATION OF STEM CELLS AND TREATMENT OF ORGAN DYSFUNCTION OR BODY INSUFFICIENCY
US20080195007A1 (en) * 2007-02-12 2008-08-14 Yury Podrazhansky Method and device for using vibroacoustic stimulaton to enhance the production of adult stem cells in living organisms
KR101569168B1 (ko) 2007-02-12 2015-11-13 안트로제네시스 코포레이션 태반 줄기세포를 이용한 염증 질환의 치료
US7674691B2 (en) * 2007-03-07 2010-03-09 International Business Machines Corporation Method of manufacturing an electrical antifuse
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
CA2700617C (en) 2007-09-28 2018-11-06 Celgene Cellular Therapeutics Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
JP5950577B2 (ja) 2008-08-20 2016-07-13 アンスロジェネシス コーポレーション 単離胎盤細胞を使用した脳卒中の治療
DK2330889T3 (en) 2008-08-20 2017-01-30 Anthrogenesis Corp Improved cell composition and process for making the same
HRP20130812T1 (en) 2008-08-22 2013-09-30 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
CN102282252B (zh) 2008-11-19 2017-07-04 人类起源公司 羊膜来源的贴壁细胞
US8586360B2 (en) 2009-07-02 2013-11-19 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
BR112012004335A8 (pt) 2009-09-02 2016-06-21 Merck Sharp & Dohme Composto, composição farmacêutica, e, uso do composto.
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
ES2646750T3 (es) 2010-01-26 2017-12-15 Anthrogenesis Corporation Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias
EP2538783B1 (en) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
IL250234B2 (en) 2010-04-07 2023-10-01 Anthrogenesis Llc Angiogenesis using placental stem cells
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
KR20180099915A (ko) 2010-07-13 2018-09-05 안트로제네시스 코포레이션 천연 킬러 세포의 생성 방법
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
AU2011352036A1 (en) 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
CN104220081A (zh) 2011-06-01 2014-12-17 人类起源公司 利用胎盘干细胞治疗疼痛
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2753334B1 (en) 2011-08-30 2022-10-19 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US9315508B2 (en) 2012-07-23 2016-04-19 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE158109C (pt)
DE270382C (pt)
DE296075C (pt)
US4318904A (en) 1980-04-25 1982-03-09 Research Corporation Peptide affinity labels for thrombin and other trypsin-like proteases
US4443609A (en) 1980-05-19 1984-04-17 Petrolite Corporation Tetrahydrothiazole phosphonic acids or esters thereof
DD158109A1 (de) 1981-04-10 1982-12-29 Gunter Fischer Verfahren zur hemmung der katalytischen aktivitaet von peptidhydrolasen
US4582821A (en) 1983-11-16 1986-04-15 E. I. Du Pont De Nemours And Company Inhibition of cyclic nucleotide independent protein kinases
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4636492A (en) 1984-08-29 1987-01-13 E. I. Du Pont De Nemours And Company Inhibition of viral protease activity by peptide halomethyl ketones
US4652552A (en) 1984-09-10 1987-03-24 E. I. Du Pont De Nemours And Company Tetrapeptide methyl ketone inhibitors of viral proteases
US4644055A (en) 1984-12-17 1987-02-17 E. I. Du Pont De Nemours And Company Method for preparing specific inhibitors of virus-specified proteases
US4664262A (en) * 1985-11-26 1987-05-12 White Pamela J Pill dispensing system
DD270382A1 (de) 1986-10-31 1989-07-26 Univ Halle Wittenberg Verfahren zur kolorimetrischen bestimmung von dipeptidylpeptidase iv mittels dipeptidhydraziden
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
JPH03504975A (ja) 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
IL91307A0 (en) 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
DE3840452A1 (de) 1988-12-01 1990-06-07 Hoechst Ag (beta)-amino-boronsaeure-derivate
DE3842197A1 (de) 1988-12-15 1990-06-21 Hoechst Ag Rasch spaltbares substrat fuer die hiv-protease
US5635386A (en) 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
DD296075A5 (de) 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
DE4033062A1 (de) 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
ES2099158T3 (es) 1990-04-14 1997-05-16 New England Medical Center Inc Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
US5378624A (en) 1990-04-23 1995-01-03 Cellpro, Incorporated Methods for removing ligands from a particle surface
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
WO1991017767A1 (en) 1990-05-21 1991-11-28 New England Medical Center Hospitals, Inc. Method of treating inhibition of dipeptidyl aminopeptidase type iv
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
FR2668069B1 (fr) * 1990-10-18 1993-02-05 Dassault Avions Dispositif, notamment autonome et portable, pour extraire de la chaleur d'une source chaude.
CA2098702A1 (en) 1990-12-28 1992-06-29 James C. Powers Peptide ketoamides, ketoacids, and ketoesters
EP0578745A1 (en) 1991-04-04 1994-01-19 The Upjohn Company Phosphorus containing compounds as inhibitors of retroviruses
IE922316A1 (en) 1991-07-17 1993-01-27 Smithkline Beecham Corp Retroviral protease inhibitors
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
AU2468392A (en) 1991-08-29 1993-04-05 Cytel Corporation Novel immunosuppressants
DK0610317T3 (da) * 1991-10-22 2001-02-19 New England Medical Center Inc Inhibitorer af dipeptidyl-aminopeptidase type IV
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
WO1993016102A1 (en) 1992-02-06 1993-08-19 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
US5296604A (en) 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
AU4794393A (en) * 1992-07-31 1994-03-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Producing increased numbers of hematopoietic cells by administering inhibitors of dipeptidyl peptidase iv
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
WO1994009132A1 (en) 1992-08-21 1994-04-28 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
FR2701951B1 (fr) 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
SG52766A1 (en) 1993-03-03 1998-09-28 Sandoz Ltd Organic compounds
US5384410A (en) 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
AU6773994A (en) 1993-04-23 1994-11-21 Cellpro, Incorporated Methods for enriching fetal progenitor cells from maternal blood
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
FR2707170A1 (fr) 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
WO1995011689A1 (en) * 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
NL9400309A (nl) 1993-11-04 1995-06-01 Eurogenetics Nv Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5489025A (en) * 1994-03-01 1996-02-06 Romick; Jerome M. Unit-dose medication dispenser and multiple-dispenser frame therefor
FR2719049B1 (fr) 1994-04-22 1996-06-14 Pasteur Institut Multireprésentation d'un analogue peptidique du substrat de la DPPIV, notamment de type KPR, afin d'inhiber l'entrée du HIV dans les cellules.
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE4416963C1 (de) 1994-05-13 1995-07-13 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Diarylprolinolen
AU2790895A (en) 1994-06-10 1996-01-05 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
FR2721611B1 (fr) 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
EP1621206A1 (en) * 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US5856571A (en) 1995-06-07 1999-01-05 Cellpro, Incorporated Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
ATE204322T1 (de) 1995-06-07 2001-09-15 Aastrom Biosciences Inc Vorrichtung und verfahren zum aufbewahren und zur züchtung biologischer zellen
DE69523956T2 (de) * 1995-12-29 2002-07-18 Alg Company, Marlborough Vermehrung von knochenmarksstützzellen
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
GB9624562D0 (en) 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
CA2304206A1 (en) 1997-09-29 1999-04-08 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
MY132924A (en) * 1998-05-04 2007-10-31 Point Therapeutics Inc Hematopoietic stimulation
CA2339537A1 (en) 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU2003248921A1 (en) 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy

Also Published As

Publication number Publication date
CA2331122A1 (en) 1999-11-11
AU770319C (en) 2004-11-25
US20070135354A1 (en) 2007-06-14
MY132924A (en) 2007-10-31
JP2002513762A (ja) 2002-05-14
TWI252107B (en) 2006-04-01
KR20010052302A (ko) 2001-06-25
EP1075266A1 (en) 2001-02-14
US6770628B2 (en) 2004-08-03
AU2004202138A1 (en) 2004-06-10
US20020013279A1 (en) 2002-01-31
PE20000481A1 (es) 2000-06-13
NZ507730A (en) 2004-02-27
WO1999056753A1 (en) 1999-11-11
AU3878199A (en) 1999-11-23
AR023628A1 (es) 2002-09-04
US6300314B1 (en) 2001-10-09
US20050037976A1 (en) 2005-02-17
IL139247A0 (en) 2001-11-25
AU770319B2 (en) 2004-02-19
NO20005488L (no) 2001-01-04
NO20005488D0 (no) 2000-10-31
US7067489B2 (en) 2006-06-27

Similar Documents

Publication Publication Date Title
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
ES2147720T3 (es) Factor de celulas madre.
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
BR9813233A (pt) Estimulação de células hematopoéticas in vitro
DK1082410T3 (da) Humane CD45 - og/eller fibroblast mesenchymale stamceller
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
NO962088L (no) Preparat for in vivo-produksjon av terapeutiske produkter
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
EP0283713A3 (en) Complexes of saponins with phospholipids and pharmaceutical and cosmetic compositions containing them
DE69718053D1 (de) in vitro methoden und verwendung von pharmazeutische zusammensetzungen für die BEHANDLUNG VON INNENOHRHAARZELLEN
DK0774005T3 (da) Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
CA2022177A1 (en) Arginine deiminase, its manufacturing method, and an anti-cancer agent containing this enzyme as an effective ingredient
TR200002248T2 (tr) Yeni dihidroksiheksanoik asit türevleri
TR200003144T2 (tr) Tiyenopirimidinler.
IL91184A0 (en) N-2,3-butadienyl tri-and tetraaminoalkane derivatives
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
CA2227711A1 (en) Thioctic acid metabolites and methods of use thereof
AU7538700A (en) 5-hydroxysapogenin derivatives with anti-dementia activity
WO2000066732A3 (en) Laminin 8 and methods for its use

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 10 (INCISO VIII) E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.